Dear Editor,rnThe pandemic of coronavirus disease 2019(COVID-19)caused by SARS-CoV-2 has posed a significant threat to global public health and economy,thus calling for the rapid development of effective therapeutics and prophylactics.Repurposing existing medicines with clinical safety pro-files offers a more rapid hope of combating COVID-19 pandemic than developing a new therapeutic.For example,remdesivir was originally developed to treat Ebola virus infection and its safety to humans has been confirmed in a phase I clinical trial(Grein et al.2020).Therefore,it immediately went to clinical trials for in vivo efficacy in treatment of COVID-19 patients after its in vitro anti-SARS-CoV-2 activity was verified(Grein et al.2020).